Study on Donor Leukocyte Telomere Length and Outcomes in Acute Leukemia Patients Receiving Allogeneic Stem Cell Transplants

What this Trial Is About

Researchers are studying patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation allo-HSCT to understand how the length of donor leukocyte telomeres relates to patient outcomes. This observational study includes patients aged 5 to 90 years who achieved complete remission and full donor engraftment after transplantation. The study was conducted at Zhejiang University schools of medicine and complies with ethical standards. The study involves no interventions or treatments it is an observational analysis. Donors leukocyte telomere lengths were measured from blood samples collected before receiving granulocyte colony-stimulating factor G-CSF mobilization. Patients and donors were grouped by donor age 40 years or older versus younger than 40 to observe differences. Participants are followed after transplantation with assessments including overall survival up to 60 months, relapse-free survival, and cumulative incidence of relapse. Researchers evaluate survival outcomes from the date of transplant until death, relapse, or end of follow-up. The study collects clinical data and donor telomere measurements to analyze prognosis in acute leukemia patients post-transplant.

A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation